← Silence Therapeutics plc
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $244k |
$5.5m
+2145.49%
|
$12.4m
+126.59%
|
$17.5m
+40.97%
|
$25.4m
+44.99%
|
$47.7m
+88.10%
|
$4.0m
-91.54%
|
$839k
-79.23%
|
|
| Cost of Revenue | $121k |
$3.8m
+3011.49%
|
$7.5m
+98.19%
|
$10.9m
+45.92%
|
$10.3m
-5.17%
|
$11.8m
+14.46%
|
$215k
-98.18%
|
$172k
-20.00%
|
|
| Cost of sales | — | ($3.8m) |
($7.5m)
-98.19%
|
($10.9m)
-45.92%
|
($10.3m)
+5.17%
|
— | — | $172k | |
| Gross Profit | $244k |
$1.7m
+603.69%
|
$5.0m
+188.82%
|
$6.6m
+33.51%
|
$15.1m
+127.41%
|
$31.4m
+108.86%
|
$344k
-98.91%
|
$667k
+93.90%
|
|
| Research And Development | $13.3m | $20.2m | $30.8m | $35.6m | $44.0m | $67.9m | $67.8m | $56.1m | |
| General and Administrative Expense | $9.6m | $14.0m | $20.0m | $19.6m | $20.6m | $26.9m | $22.3m | $21.7m | |
| Restructuring And Mergern Acquisition | — | — | — | — | — | $0 | $1.3m | $1.3m | |
| Operating expenses: | |||||||||
| Other Non Operating Income Expenses | — | — | — | — | — | $13.7m | $7.5m | — | |
| Operating Income (Loss) | ($22.7m) |
($35.8m)
-57.68%
|
($45.8m)
-27.80%
|
($48.6m)
-6.07%
|
($49.6m)
-2.08%
|
($63.3m)
-27.65%
|
($91.1m)
-43.84%
|
($77.1m)
+15.37%
|
|
| Interest Expense On Lease Liabilities | $33k | $16k | $8k | $47k | $34k | — | — | ($44k) | |
| Interest Expense | — | — | $11k | $57k | $43k | — | — | ($44k) | |
| Interest Income | — | — | — | — | — | $4.5m | $3.5m | $5.3m | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | $646k | ($8.5m) | — | |
| Gain On Sale Of Security | — | — | — | — | — | $646k | ($8.5m) | ($5.2m) | |
| Other Income | — | — | — | — | — | $4.5m | $3.5m | — | |
| Finance and other income | $27k | $129k | $10k | $1.3m | $1.4m | — | — | — | |
| Finance and other expenses | ($163k) | ($323k) | ($52k) | ($47k) | ($2.2m) | — | — | — | |
| Other Income Expense | — | — | — | — | — | $14.4m | ($2.3m) | ($1.4m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | ($89.7m) | ($75.0m) | |
| Pre-Tax Income | — | — | — | — | — | ($44.5m) | ($88.6m) | ($75.0m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | ($44.5m) | ($88.6m) | ($75.0m) | |
| Current Tax Expense (Income) | — | — | ($6.4m) | ($7.3m) | ($7.0m) | — | — | — | |
| Deferred Tax Expense (Income) | — | — | $0 | $0 | $0 | — | — | — | |
| Current Income Tax Expense (Benefit) | — | — | — | — | — | $845k | $11k | $11k | |
| Income Tax Expense Continuing Operations | ($3.3m) | ($3.5m) | ($6.4m) | ($6.9m) | ($7.0m) | — | — | $11k | |
| Net Income From Continuing And Discontinued Operation | — | — | — | — | — | ($45.3m) | ($88.6m) | ($75.0m) | |
| Earnings Per Share, Basic | — | — | — | — | — | ($0.33) | ($0.63) | ($1.62) | |
| Earnings Per Share, Diluted | — | — | — | — | — | ($0.33) | ($0.63) | ($1.62) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | 138.8m | 141.7m | 47.2m | |
| Basic Average Shares | — | — | — | — | — | $46.3m | $47.2m | $47.2m | |
| Diluted Average Shares | — | — | — | — | — | $46.3m | $47.2m | $47.2m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 138.8m | 141.7m | 47.2m | |
| Additional Financial Items | |||||||||
| Applicable Tax Rate | $0 | $0 | $0 | $0 | $0 | — | — | — | |
| Finance Income | $27k | $129k | $10k | $1.3m | $1.4m | — | — | — | |
| Goodwill, Impairment Loss | — | — | — | — | — | $0 | $0 | — | |
| Profit Loss Before Tax | ($22.9m) | ($36.0m) | ($45.9m) | ($47.4m) | ($50.3m) | — | — | — | |
| Profit Loss From Operating Activities | ($22.7m) | ($35.8m) | ($45.8m) | ($48.6m) | ($49.6m) | ($63.3m) | ($91.1m) | — | |
| Loss for the year before taxation | ($22.9m) | ($36.0m) | ($45.9m) | ($47.4m) | ($50.3m) | — | — | — | |
| Taxation | $3.3m | $3.5m | $6.4m | $6.9m | $7.0m | — | — | — | |
| Loss for the year after taxation | ($19.6m) | ($32.5m) | ($39.4m) | ($40.5m) | ($43.3m) | — | — | — | |
| Diluted EPS | — | — | — | — | — | ($0.99) | ($1.89) | ($1.62) | |
| Diluted NI Availto Com Stockholders | — | — | — | — | — | ($45.3m) | ($88.6m) | ($75.0m) | |
| Normalized EBITDA | — | — | — | — | — | ($63.4m) | ($79.4m) | ($76.6m) | |
| Normalized Income | — | — | — | — | — | ($45.8m) | ($81.3m) | ($71.1m) | |
| Other Gand A | — | — | — | — | — | $26.9m | $22.3m | — | |
| Reconciled Depreciation | — | — | — | — | — | $593k | $555k | $523k | |
| Selling General And Administration | — | — | — | — | — | $26.9m | $22.3m | — | |
| Special Income Charges | — | — | — | — | — | $0 | ($1.3m) | ($1.3m) | |
| Tax Effect Of Unusual Items | — | — | — | — | — | $162k | ($2.4m) | ($2.6m) | |
| Tax Provision | — | — | — | — | — | $845k | $11k | $11k | |
| Tax Rate For Calcs | — | — | — | — | — | $0 | $0 | $0 | |
| Employee Benefits Expense | $7.2m | $12.1m | $21.3m | $26.9m | $30.4m | — | — | — | |
| Expense From Share-Based Payment Transactions With Employees | $584k | $4.4m | $8.6m | $10.3m | $13.1m | — | — | — | |
| Finance Costs | $163k | $323k | $52k | $47k | $2.2m | — | — | — | |
| Operating Expense | — | — | — | — | — | $94.8m | $90.1m | $77.9m | |
| Rent Expense Supplemental | — | — | $448k | $410k | — | — | — | $410k | |
| Net Foreign Exchange Loss | $130k | $307k | $44k | — | $2.1m | — | — | — | |
| Total Unusual Items | — | — | — | — | — | $646k | ($9.8m) | ($6.5m) | |
| Total Expenses | — | — | — | — | — | $106.6m | $90.3m | $77.9m |